Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

Treatment outcomes and life expectancy news

Show

From To
More than 1 year to HIV control raises failure risk almost 10-fold

Failure to reach an undetectable viral load in the first year of antiretroviral therapy (ART) led to nearly a 10-fold higher risk of subsequent virologic failure in a 17,000-person North American analysis [1]. Taking more than 1 year to control HIV did not confer a higher risk of low-level viremia or viral blips in this 6-year study.

Published
15 March 2019
From
NATAP
Up to 95% virologic response rate with rapid ART in safety-net clinic

Up to 95% of people with newly diagnosed HIV and beginning antiretroviral therapy (ART) within a week of diagnosis reached a viral load below 50 copies in the first year of therapy. High proportions of people in this San Francisco safety-net clinic had a substance use disorder, a major mental health diagnosis, or unstable housing.

Published
14 March 2019
From
NATAP
Wider ART Rollout Tied to Declines in HIV Mortality in Kenya

Both all-cause mortality and mortality among HIV-positive people dropped in Western Kenya following a scale-up of antiretroviral therapy (ART), a researcher said here. From 2011 to 2016, all-cause mortality dropped from 10.0 per 1,000 person years (95% CI 8.4-11.7) to 7.5 per 1,000 person years (95% CI 5.8-9.1), reported Emily C. Zielinski-Gutierrez, DrPH, of the CDC.

Published
12 March 2019
From
MedPage Today
Multiple benefits to scaling up universal test and treat in Africa

As well as the important findings of PopART, the largest HIV prevention trial ever conducted, this week’s Conference on Retroviruses and Opportunistic Infections (CROI) in Seattle heard about

Published
08 March 2019
By
Roger Pebody
DAA treatment reduces the risk of death and liver cancer in people with hepatitis C

Treatment with direct-acting antivirals (DAAs) reduced the risk of death, liver cancer and death from liver-related causes in French people with hepatitis C, according to

Published
13 February 2019
By
Keith Alcorn
Glimmers of hope: moving towards better HIV and TB treatment in eastern Europe

Eastern Europe continues to have one of the worst HIV epidemics in the world outside sub-Saharan Africa, with the worst linkage to care of any region in

Published
07 February 2019
By
Gus Cairns
Is ageing in people living with HIV accelerated or accentuated?

Earlier than normal ageing in people living with HIV has been debated for many years. The issue emerged when it became clear that HIV-positive people had an

Published
30 January 2019
By
Alain Volny-Anne
Uganda: Financial incentives do not boost HIV viral suppression rate

Financial incentives had no effect on viral suppression among HIV-positive adults in Uganda, according to a recent study. Researchers said these findings suggest a need for better interventions to promote the achievement of viral suppression.

Published
25 January 2019
From
Healio
Atripla or efavirenz plus Truvada failed one in 16 people in first year

Estimates of how often people on antiretroviral therapy (ART) do not remain virally undetectable are important both in order to gauge the potency of ART, and to

Published
21 January 2019
By
Gus Cairns
HIV treatment outcomes continue to get better, says large analysis

The efficacy of first-line antiretroviral therapy (ART) continues to improve, according to an analysis of outcomes in 78,000 people in 181 studies, published in AIDS by Professor

Published
27 December 2018
By
Michael Carter
← First12345...39Next →

Filter by country

Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap
close

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.